Stocks · News reference
Immunome, Inc. presented new clinical data for its investigational gamma secretase inhibitor, varegacestat, at the 2026 European Society for Medical Oncology (ESMO) Congress.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immunome, Inc. announced it will present initial first-in-human clinical data from its ongoing Phase 1 study of IM-1021, an ROR1-targeted antibody-drug conjugate, at the 68th American Society of Hematology Annual Meeting.
Immunome, Inc. announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for varegacestat, an investigational gamma secretase inhibitor for treating adults with desmoid tumors.
An analyst has initiated research coverage on Immunome (IMNM) as part of a broader inaugural report covering thirteen biotechnology companies.
William Blair analyst Alethia Young initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating.